Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00017511 · ClinicalTrials.gov registry record · Phase 3
Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer
A Phase 3 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00017511: Completed Phase 3 study, sponsored by Daiichi Sankyo.
NCT00017511 is a Phase 3 study that has completed, run by Daiichi Sankyo. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00017511, a Phase 3 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
RATIONALE: Cevimeline may be effective in treating dry mouth that is caused by radiation therapy for head and neck cancer. It is not yet known if cevimeline is more effective than no therapy in treating dry mouth caused by radiation therapy. PURPOSE: Randomized phase III trial to determine the effectiveness of cevimeline in treating patients who have dryness of the mouth caused by radiation therapy for head and neck cancer.
Interventions
- DRUG cevimeline hydrochloride
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-06 |
| Est. Completion | 2003-03 |
| Phase | Phase 3 |
What the finished NCT00017511 record still lists
NCT00017511 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which cevimeline hydrochloride is the first listed.
NCT00017511 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00017511 about?
NCT00017511 is a clinical study titled "Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer". RATIONALE: Cevimeline may be effective in treating dry mouth that is caused by radiation therapy for head and neck cancer. It is not yet known if cevimeline is more effective than no therapy in treating dry mouth caused by radiation therapy. PURPOSE: Randomized phase III trial to determine the effe...
What is the current status of trial NCT00017511?
This trial is currently completed. It is a Phase 3 study. The study started on 2001-06. Estimated completion is 2003-03.
What interventions are being tested in trial NCT00017511?
The interventions under investigation include: cevimeline hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00017511?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia